Bank Julius Baer & Co
RNTX

Bank Julius Baer & Co’s Rein Therapeutics RNTX Stock Holding History

Bank Julius Baer & Co’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,000
Closed -$25K – 872
2021
Q2 		$25K Hold
1,000
– – ﹤0.01% 744
2021
Q1 		$29K Buy
1,000
+231
+30% +$7.92K ﹤0.01% 725
2020
Q4 		$16K Buy
+769
New +$19.2K ﹤0.01% 759

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank Julius Baer & Co's RNTX Position: Q3 2021 in Review

Bank Julius Baer & Co sold out of Rein Therapeutics (RNTX) in Q3 2021, closing a stake of 1,000 shares — an estimated $25K sold.

Bank Julius Baer & Co first reported a position in RNTX in Q4 2020 and held it in 3 quarters. The position peaked at $29K in Q1 2021. 43 funds tracked by Wall St. Rank hold RNTX as of Q3 2021.

  • Bank Julius Baer & Co reported no remaining Rein Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 1,000 Rein Therapeutics shares in Q3 2021, an estimated $25K.
  • Bank Julius Baer & Co first reported a position in Rein Therapeutics in Q4 2020 and held it in 3 quarters.
  • Bank Julius Baer & Co's Rein Therapeutics position peaked at $29K in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2021.

Based on Bank Julius Baer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.